Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

NCT02048722 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT02048722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02048722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
June 13, 2014
Completion date
October 12, 2021
Enrollment
31 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

adult angiosarcoma, recurrent adult soft tissue sarcoma, stage iii adult soft tissue sarcoma, stage iv adult soft tissue sarcoma